Table 1 Demographic and clinical characteristics of participants.

From: Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial

Characteristics

LAF& ESO (N = 24)

ESO (N = 24)

P-value

Male

14 (58.3%)

14 (58.3%)

1.000

Age (year)

53.5 (43.5, 58.8)

53.5 (42.8, 63.8)

0.910

BMI (kg*m-2)

23.3 (20.5, 27.8)

23.1 (20.1, 26.6)

0.635

Drinking

11(45.8%)

9(37.5%)

0.558

Smoking

7(37.5%)

6(25.0%)

0.745

PPI Response

16 (66.7%)

15 (62.5%)

0.763

Combined diseases

Hypertension

4(16.7%)

7(29.2%)

0.303

Diabetes

1(4.2%)

3(12.5%)

0.609

Hp infection

4(16.7%)

2(8.3%)

0.666

pharyngitis

9(37.5%)

9(37.5%)

1.000

Duration of GERD

0.485

1–3 months

2(8.3%)

3(12.5%)

 

3–6 months

1(4.2%)

1(4.2%)

 

6 months-1 year

1(4.2%)

4(16.7%)

 

 > 1 year

20(83.3%)

16(66.7%)

 

Symptom scale scores

GERD-Q

12.0 (11.0, 13.0)

11.5 (10.0, 12.0)

0.276

RDQ

15.0 (8.5, 21.0)

15.0 (10.5, 18.0)

0.820

RSI

7.0 (4.0, 15.5)

5.0 (4.0, 12.3)

0.950

PSQI

11.5 (7.3, 13.8)

11.0 (7.3, 14.8)

0.187

Esophagitis

8(33.3%)

10(41.7%)

0.551

HREM parameters

LES pressure(mmHg)

10.5 (8.0, 17.0)

14.0 (7.5, 19.0)

0.531

4 s IRP (mmHg)

2.5 (2.0, 7.2)

3.1 (0.0, 5.9)

0.428

Hypotensive EGJ

8(42.1%)

6(30.0%)

0.431

EGJ II/III

3 (15.8%)

5 (25.0%)

0.695

IEM

9 (47.4%)

10(50.0%)

0.869

  1. GERD-Q: GERD-questionnaire; RDQ: Reflux disease questionnaire; RSI: Reflux symptom index; PSQI: Pittsburgh Sleep Quality Index; HREM: High-resolution esophageal manometry; LES: low esophageal sphincter; IRP: Integrated relaxation pressure; EGJ, esophagogastric junction; IEM, ineffective esophageal motility.
  2. : HREM parameters were compared between nineteen patients and twenty patients in LAF & ESO group and ESO group, respectively.